Post-acute sequalae of COVID-19 three to twelve months after infection: Delta versus Omicron.

Autor:	de Bruijn S; Center for Infectious Disease Control, National Institute for Public Health and the Environment (RIVM), Antonie van Leeuwenhoeklaan 9, 3721 MA Bilthoven, the Netherlands. Electronic address: Simeon.de.bruijn@rivm.nl., Tulen AD; Center for Infectious Disease Control, National Institute for Public Health and the Environment (RIVM), Antonie van Leeuwenhoeklaan 9, 3721 MA Bilthoven, the Netherlands., Rodenburg J; Department of Statistics, Data Science and Mathematical Modelling, National Institute for Public Health and the Environment (RIVM), Antonie van Leeuwenhoeklaan 9, 3721 MA Bilthoven, the Netherlands., Boshuizen H; Department of Statistics, Data Science and Mathematical Modelling, National Institute for Public Health and the Environment (RIVM), Antonie van Leeuwenhoeklaan 9, 3721 MA Bilthoven, the Netherlands., Schipper M; Department of Statistics, Data Science and Mathematical Modelling, National Institute for Public Health and the Environment (RIVM), Antonie van Leeuwenhoeklaan 9, 3721 MA Bilthoven, the Netherlands., Mutubuki EN; Center for Infectious Disease Control, National Institute for Public Health and the Environment (RIVM), Antonie van Leeuwenhoeklaan 9, 3721 MA Bilthoven, the Netherlands., Knoop H; Department of Medical Psychology and Amsterdam Public Health from the Amsterdam UMC, location University of Amsterdam, Meibergdreef 9, Amsterdam, the Netherlands., Franz E; Center for Infectious Disease Control, National Institute for Public Health and the Environment (RIVM), Antonie van Leeuwenhoeklaan 9, 3721 MA Bilthoven, the Netherlands., van der Maaden T; Center for Infectious Disease Control, National Institute for Public Health and the Environment (RIVM), Antonie van Leeuwenhoeklaan 9, 3721 MA Bilthoven, the Netherlands., Hof SVD; Center for Infectious Disease Control, National Institute for Public Health and the Environment (RIVM), Antonie van Leeuwenhoeklaan 9, 3721 MA Bilthoven, the Netherlands., van Hoek AJ; Center for Infectious Disease Control, National Institute for Public Health and the Environment (RIVM), Antonie van Leeuwenhoeklaan 9, 3721 MA Bilthoven, the Netherlands., Wijngaard CCVD; Center for Infectious Disease Control, National Institute for Public Health and the Environment (RIVM), Antonie van Leeuwenhoeklaan 9, 3721 MA Bilthoven, the Netherlands.
Jazyk:	angličtina
Zdroj:	International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases [Int J Infect Dis] 2024 Nov 14, pp. 107302. Date of Electronic Publication: 2024 Nov 14.
DOI:	10.1016/j.ijid.2024.107302
Abstrakt:	Objectives: Studies have shown temporal changes in Post-acute sequalae of COVID-19 (PASC) prevalence for early SARS-CoV-2 variants, though often lacking controls. This prospective study assesses the prevalence of symptoms in Delta and Omicron infected cases up to 12 months compared to population controls. Methods: Adult participants filled out three-monthly surveys (T0-T12) between July 2021 and August 2023. Cases were recruited with a positive SARS-CoV-2 test during Delta or Omicron domination. Population controls were randomly invited from the Dutch Personal Records Database. Participants indicated presence of 13 PASC-associated symptoms, and severity scores of fatigue, cognitive impairment, dyspnoea and pain. PASC prevalence was defined as the excess prevalence of having ≥ one PASC-associated symptom in cases compared to population controls. Results: PASC prevalence was 34.3% at T3 and decreased to 21.7% at T12 for Delta and decreased from 18.7% at T3 to 16.7% at T12 for Omicron. At T12 the difference between Delta and Omicron was not significant. Delta cases generally had higher excess symptom scores for fatigue, dyspnoea and cognitive impairment than Omicron. Conclusion: In the first nine months after infection, PASC prevalence was higher for Delta than Omicron, but the difference reduced over time and approximated after twelve months. (Copyright © 2024. Published by Elsevier Ltd.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu